ARTH Stock UPDATES Arch Therapeutics Inc. (ARTH) 0.1805 08/30/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arch Therapeutics Inc. (ARTH) 0.1805 $ARTH

Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
Marketwire - Tue Aug 26, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.

Arch Therapeutics Announces Positive Preclinical Data From Its Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinner
Marketwire - Mon Aug 25, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, today announced positive data in an initial preclinical study assessing the use of its AC5 Surgical Hemostatic Device(TM) in animals receiving an anticoagulant medication (i.e. blood thinner).

Arch Therapeutics Announces Third Quarter 2014 Results
Marketwire - Wed Aug 06, 6:29AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, today announced financial results for the three and nine months ended June 30, 2014.

Arch Therapeutics Announces Collaboration With University College Cork School of Pharmacy
Marketwire - Tue Jul 22, 7:31AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), has entered into a new collaboration agreement with the University College Cork (UCC) School of Pharmacy in Cork, Ireland, of the National University of Ireland (NUI), focusing on development of hemostasis and sealant products.

Arch Therapeutics Selects BSI as Its European Union Notified Body
Marketwire - Tue Jul 15, 7:31AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has selected the British Standards Institution ("BSI" as its Notified Body. A Notified Body is an organization that has been accredited by a member state of the European Union to assess whether a product meets certain preordained standards to receive a CE Mark designation.

Arch Therapeutics Appoints Richard Davis as Chief Financial Officer
Marketwire - Mon Jul 07, 5:07PM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Richard Davis as Chief Financial Officer and Treasurer as it continues to expand its team. Mr. Davis, who has worked as a consultant at Arch since April, has started full time in his new role effective today, July 7, 2014. The Company's current Chief Financial Officer and Treasurer, Alan Barber, has resigned from his position effective July 7, 2014 and has become an advisor to the Company.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23
Marketwire - Mon Jun 16, 7:15AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announces that co-founder and inventing scientist Dr. Rutledge Ellis-Behnke will present his work using AC5(TM) at the Seventh Annual European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on Monday, June 23.

Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering and Quality Systems and Peter LaCrosse as Chief of Staff
Marketwire - Tue Apr 01, 7:03AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Chirag Shah, PhD as Vice President of Research and Development Engineering and Quality Systems, effective April 7, 2014, and has appointed Peter A. LaCrosse as Chief of Staff, effective immediately.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March
Marketwire - Wed Mar 26, 8:03AM CDT
Rutledge Ellis-Behnke, PhD, co-founder and inventing scientist at Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, presents his work using AC5(TM) at two scientific meetings.

IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:

Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 8:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3rd at 12:05 PM EST.

10-Q: ARCH THERAPEUTICS, INC.
Edgar Online - Fri Feb 14, 7:42AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Arch Therapeutics Secures $2.85 Million Private Placement
Marketwire - Mon Feb 10, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care has closed a previously announced private placement to accredited individual and institutional investors (the "Investors" .

OTC Daily Alert Stock Watch - Arch Therapeutics, Inc. (OTCQB: ARTH)
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Arch Therapeutics Announces $2.85 Million Private Placement
Marketwire - Fri Jan 31, 5:00AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce today its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share, pursuant to the terms of a securities purchase agreement dated January 30, 2014. The private placement is expected to close on or about February 4, 2014, subject to customary closing conditions.

Arch Therapeutics Presents 2014 Milestones During Live Webcast
Marketwire - Wed Jan 22, 10:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., presented its calendar year 2014 milestone targets during a live audio and high-definition video webcast on Wednesday, January 22 at 10:30AM Eastern Time from the Noble Financial Capital Markets' Tenth Annual Equity Conference in South Florida.

Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference
Marketwire - Tue Jan 14, 8:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Wednesday, January 22 at 10:30AM Eastern Time.

Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference
Marketwire - Wed Jan 08, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Terrence W. Norchi, M.D., CEO of Arch Therapeutics will present at The Biotech Showcase(TM) 2014 conference on Monday, January 13th, at 5:00PM PST. Attendees will find the presentation scheduled for "Track C" in the Mission II room at that time. Dr. Norchi's presentation will provide insights into the Company's ongoing activities to commercially develop novel technologies into a suite of new products targeting markets of unmet clinical need.

Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27
Marketwire - Fri Sep 20, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the Boulder Peptide Symposium 2013. The conference is being held September 25-27, 2013, at the St Julien Hotel in Boulder, Colorado.

Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
Marketwire - Tue Sep 03, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference. The conference, sponsored by H.C. Wainwright & Co., LLC, is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 181

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 118

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 473

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 102

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 372

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 66

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 221

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

GreenCore Solutions Unveils Innovative Partnership for Eco-Friendly Diapers

Updated Category News Views 165

New Collaboration to Enhance Retail Visibility GreenCore Solutions Corp., a frontrunner in eco-friendly diaper innovation, has joined forces with Emerson TEN OÜ. This strategic partnership aims to elevate the visibility of GreenCore's TreeFree Diaper products across European retail settings, including grocery and convenience stores. Transforming the Shopping Experience...

Continue Reading
Oman's Stock Exchange Sees Unprecedented Growth to $8.45 Billion

Updated Category News Views 339

Oman's Muscat Stock Exchange Achieves Significant Trading Growth Recent reports indicate that Oman's Muscat Stock Exchange (MSX) has experienced a remarkable performance, marking the highest trading values seen in many years. Fueled by reforms initiated by the Oman Investment Authority (OIA), the exchange has recorded an impressive trading value of approximately USD 8.45...

Continue Reading
Gloo Partners with Servant to Transform Faith-Based Organizations

Updated Category News Views 409

Gloo's Strategic Investment in Servant In an exciting new development for the faith ecosystem, Gloo has announced a significant investment in Servant, a leading consultancy dedicated to assisting organizations in their growth and digital transformation efforts. This partnership highlights Gloo's commitment to enhancing the capabilities of various faith-based...

Continue Reading
Movate Enhances AI Solutions by Acquiring Prescience for Growth

Updated Category News Views 332

Acquisition Announcement by Movate Movate, a prominent provider of digital technology services, has made a strategic move by acquiring Prescience, a key player in the field of data science and artificial intelligence. This acquisition marks a significant step for Movate as it aims to embed AI deeply into its service offerings. Through this merger, Movate seeks to enable...

Continue Reading
Stellantis Faces Rising Tensions as UAW Considers Strikes Ahead

Updated Category News Views 88

Tensions Rise Between Stellantis and UAW Stellantis, the French-Italian automotive powerhouse, is facing growing scrutiny as the United Auto Workers (UAW) union gears up for potential strikes due to allegations of contract violations. This situation emerges almost a year after a major national walkout, which led to significant losses for the Detroit Three automakers and...

Continue Reading